Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Net Income towards Common Stockholders (2017 - 2020)

Historic Net Income towards Common Stockholders for Cogent Biosciences (COGT) over the last 4 years, with Q4 2020 value amounting to -$11.4 million.

  • Cogent Biosciences' Net Income towards Common Stockholders fell 59564.65% to -$11.4 million in Q4 2020 from the same period last year, while for Sep 2021 it was -$11.4 million, marking a year-over-year increase of 8334.87%. This contributed to the annual value of -$321.7 million for FY2025, which is N/A changed from last year.
  • According to the latest figures from Q4 2020, Cogent Biosciences' Net Income towards Common Stockholders is -$11.4 million, which was down 59564.65% from -$57.2 million recorded in Q3 2020.
  • Cogent Biosciences' Net Income towards Common Stockholders' 5-year high stood at $2.3 million during Q4 2019, with a 5-year trough of -$57.2 million in Q3 2020.
  • Moreover, its 4-year median value for Net Income towards Common Stockholders was -$8.0 million (2018), whereas its average is -$10.9 million.
  • Per our database at Business Quant, Cogent Biosciences' Net Income towards Common Stockholders surged by 12669.07% in 2019 and then tumbled by 59564.65% in 2020.
  • Cogent Biosciences' Net Income towards Common Stockholders (Quarter) stood at -$6.7 million in 2017, then decreased by 28.33% to -$8.6 million in 2018, then skyrocketed by 126.69% to $2.3 million in 2019, then tumbled by 595.65% to -$11.4 million in 2020.
  • Its Net Income towards Common Stockholders stands at -$11.4 million for Q4 2020, versus -$57.2 million for Q3 2020 and -$7.4 million for Q2 2020.